96 related articles for article (PubMed ID: 22829710)
1. Expression of Somatostatin Receptor (SSTR) Subtypes (SSTR-1, 2A, 3, 4 and 5) in Neuroendocrine Tumors Using Real-time RT-PCR Method and Immunohistochemistry.
Mizutani G; Nakanishi Y; Watanabe N; Honma T; Obana Y; Seki T; Ohni S; Nemoto N
Acta Histochem Cytochem; 2012 Jun; 45(3):167-76. PubMed ID: 22829710
[TBL] [Abstract][Full Text] [Related]
2. Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigation.
Pisarek H; Stepień T; Kubiak R; Borkowska E; Pawlikowski M
Thyroid Res; 2009 Jan; 2(1):1. PubMed ID: 19173713
[TBL] [Abstract][Full Text] [Related]
3. Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3.
Hinterleitner M; Pfeiffer R; Trautwein NF; Sipos B; Singer S; Nadalin S; Königsrainer A; Lauer UM; la Fougère C; Zender L; Hinterleitner C
Front Endocrinol (Lausanne); 2023; 14():1285529. PubMed ID: 38260136
[TBL] [Abstract][Full Text] [Related]
4. Expression of somatostatin receptors 2 and 5 in circulating tumour cells from patients with neuroendocrine tumours.
Childs A; Vesely C; Ensell L; Lowe H; Luong TV; Caplin ME; Toumpanakis C; Thirlwell C; Hartley JA; Meyer T
Br J Cancer; 2016 Dec; 115(12):1540-1547. PubMed ID: 27875519
[TBL] [Abstract][Full Text] [Related]
5. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies.
Kulaksiz H; Eissele R; Rössler D; Schulz S; Höllt V; Cetin Y; Arnold R
Gut; 2002 Jan; 50(1):52-60. PubMed ID: 11772967
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive genomic and transcriptomic characterization of high-grade gastro-entero-pancreatic neoplasms.
Angerilli V; Sabella G; Simbolo M; Lagano V; Centonze G; Gentili M; Mangogna A; Coppa J; Munari G; Businello G; Borga C; Schiavi F; Pusceddu S; Leporati R; Oldani S; Fassan M; Milione M
Br J Cancer; 2024 May; ():. PubMed ID: 38729995
[TBL] [Abstract][Full Text] [Related]
7. Comparing the use of radiolabeled SSTR agonists and an SSTR antagonist in breast cancer: does the model choice influence the outcome?
Dalm SU; de Jong M
EJNMMI Radiopharm Chem; 2017; 2(1):11. PubMed ID: 29503852
[No Abstract] [Full Text] [Related]
8. Somatostatin receptor immunohistochemistry in neuroendocrine tumors: comparison between manual and automated evaluation.
Kaemmerer D; Athelogou M; Lupp A; Lenhardt I; Schulz S; Luisa P; Hommann M; Prasad V; Binnig G; Baum RP
Int J Clin Exp Pathol; 2014; 7(8):4971-80. PubMed ID: 25197368
[TBL] [Abstract][Full Text] [Related]
9. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Blumberg J; Ruszniewski P;
N Engl J Med; 2014 Jul; 371(3):224-33. PubMed ID: 25014687
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
[TBL] [Abstract][Full Text] [Related]
11. The Role of Receptor-Ligand Interaction in Somatostatin Signaling Pathways: Implications for Neuroendocrine Tumors.
Milewska-Kranc A; Ćwikła JB; Kolasinska-Ćwikła A
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201544
[TBL] [Abstract][Full Text] [Related]
12. First preclinical evaluation of [
Handula M; Beekman S; Konijnenberg M; Stuurman D; de Ridder C; Bruchertseifer F; Morgenstern A; Denkova A; de Blois E; Seimbille Y
EJNMMI Radiopharm Chem; 2023 Jun; 8(1):13. PubMed ID: 37389800
[TBL] [Abstract][Full Text] [Related]
13. Reassessment of somatostatin receptor SST4 expression in bronchopulmonary and gastroenteropancreatic neuroendocrine neoplasms using the novel rabbit monoclonal anti-human SST4 antibody 7H49L61.
Ehms B; Kaemmerer D; Sänger J; Schulz S; Lupp A
Sci Rep; 2022 Aug; 12(1):14722. PubMed ID: 36042228
[TBL] [Abstract][Full Text] [Related]
14. Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies.
Lee L; Ramos-Alvarez I; Jensen RT
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267558
[No Abstract] [Full Text] [Related]
15. High-risk pituitary adenomas and strategies for predicting response to treatment.
Kontogeorgos G; Thodou E; Osamura RY; Lloyd RV
Hormones (Athens); 2022 Mar; 21(1):1-14. PubMed ID: 35061210
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant.
Pivonello R; Munster PN; Terzolo M; Ferrigno R; Simeoli C; Puglisi S; Bali U; Moraitis AG
Front Endocrinol (Lausanne); 2021; 12():793262. PubMed ID: 35058882
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets.
Maharjan CK; Ear PH; Tran CG; Howe JR; Chandrasekharan C; Quelle DE
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680266
[TBL] [Abstract][Full Text] [Related]
18. Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview.
Cimini A; Ricci M; Russo F; Egidi M; Calabria F; Bagnato A; Schillaci O; Chiaravalloti A
Pharmaceuticals (Basel); 2021 Aug; 14(9):. PubMed ID: 34577572
[TBL] [Abstract][Full Text] [Related]
19. Kidney Protection with the Radical Scavenger α
Kristiansson A; Örbom A; Vilhelmsson Timmermand O; Ahlstedt J; Strand SE; Åkerström B
Antioxidants (Basel); 2021 Aug; 10(8):. PubMed ID: 34439519
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
